Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance

@article{Engelhardt1995AntiinflammatoryAA,
  title={Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance},
  author={Guenther Dr Engelhardt and Daisuke Homma and Kristina Schlegel and Rene Utzmann and C. Schnitzler},
  journal={Inflammation Research},
  year={1995},
  volume={44},
  pages={423-433}
}
The anti-inflammatory, analgesic and antipyretic properties of the new non-steroidal anti-inflammatory agent, meloxicam, were investigated in a variety of animal models and compared with the properties of piroxicam, diclofenac, indomethacin and several other NSAIDs.With respect to the total effect of a single oral dose, the anti-exudative effect of meloxicam on carrageenaninduced oedema in the rat exceeded that of all the NSAIDs included in the comparison. Additionally, meloxicam showed the… 

Acute studies on safety index of nonsteroidal anti-inflammatory drugs in rats

The safety index of preferential COX-2 inhibitor (nimesulide, meloxicam) was investigated using carrageenan-induced paw oedema and acute ulcerogenic model in rats, compared with the classical NSAIDs (naproxen, indomethacin).

A comparison between the effects of meloxicam and other nsaids on the production of oxyradicals by human polymorphonuclear leucocytes

Meloxicam is a potent inhibitor of oxyradical production at drug concentrations comparable with those encountered during therapy and, while relatively complex, involves effects which are stimulus dependent and myeloperoxidase sensitive.

Comparative Evaluation of the Analgesic Effect of Brand and Generics of Meloxicam tablets Available in markets

The analgesic effect of the generics (Neoxicam, Coxicam, Oximal) proved to be as good as the brand (Mobic) in rats.

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety

The pharmacokinetics of meloxicam enables once daily application, which increases compliance compared with some shorter acting NSAIDs; however, long-term clinical data clearly demonstrating safety and efficacy advantages are lacking.

Role of Indomethacin in Acute Pain and Inflammation Management: A Review of the Literature

This review provides an historic overview of indomethacin and its efficacy compared with other commonly used analgesics, and discusses new indometHacin drug products.

Analgesic, Anti-Inflammatory and Ulcerogenic Studies of Meloxicam Solid Dispersion in Rodents

Results indicate that both physical mixture and solid dispersion possess better analgesic and anti-inflammatory properties with less ulcerogenic potential as compared to pure meloxicam.

Investigations on analgesic, anti-inflammatory and ulcerogenic potential of meloxicam solid dispersion prepared with skimmed milk.

Results indicate that solid dispersion possess better analgesic and anti-inflammatory properties with less ulcerogenic potential as compared to pure meloxicam.

Interaction of meloxicam and phenylbutazone on the level of cyclooxygenase-2 in mice

The reason for the recent study was to inspect the therapeutic efficacy of meloxicam and phenylbutazone alone with their analgesic interaction and their subsequent inhibitory interaction at the level

Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat

Findings indicate that the action of meloxicam and piroxicam differs from that of diclofenac and tenidap in adjuvant arthritis in the Lewis rat.
...

References

SHOWING 1-10 OF 60 REFERENCES

Meloxicam: A toxicology overview

Toxicological testing of meloxicam in animals suggests that acute oral overdosage is unlikely to cause severe toxicity in man, and the drug in animal tests exhibits potential antiarthritic action and has a wider spectrum of anti-inflammatory activity than currently available NSAIDs.

A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatoid drugs.

  • B. WhittleJ. Vane
  • Medicine, Biology
    Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement
  • 1984
The development of nonsteroid anti-rheumatic drugs which have minimal action on prostaglandin production by the gastro-intestinal tract and exhibit reduced gastrointestinal toxicity appears to be a feasible proposition.

Biological activity of the main metabolites of meloxicam.

It can be concluded that the metabolites of Meloxicam do not change renal blood flow and therefore have no capability for nephrotoxicity, in accordance with the observations in the rat kidney during subacute and chronic toxicity studies, where no neph rotoxic effects could be detected after therapeutic doses.

Effect of a new anti-inflammatory compound, CGP 28237, on arachidonate metabolism in rat gastrointestinal tissue

CGP 28237 (5-methlysulfonylamino-6-phenoxy1-indanone), a new NSAID, is equipotent with indomethacin in the rat adjuvant arthritis test and has an outstanding gastrointestinal tolerability in this species up to the highest dose tested.

Comparative effect of antirheumatic drugs on adjuvant-induced polyarthritis in rats.

  • J. WardR. S. Cloud
  • Medicine, Biology
    The Journal of pharmacology and experimental therapeutics
  • 1966
Adjuvant arthritis of rats is established as an experimental model for testing antiartliritic drugs and it is suggested that this model would be more useful for drug evaluation with improved techniques for measuring joint swelling and tenderness.

Analgesic antipyretic drugs as antagonists of bradykinin.

The antagonism between analgesic antipyretic drugs and bradykinin was examined quantitatively, using the bronchoconstrictor response of guinea-pigs in vivo and a method of measuring the potency of this anti-bradykinIn action was developed.

An analysis of piroxicam in rodent models of arthritis

Piroxicam inhibited rat adjuvant disease and its associated manifestations, which include erosion of bone and cartilage, soft tissue swelling and disease-induced weight loss, in several rodent models of arthritis.

Distribution of [14C]meloxicam in joints of rats with adjuvant arthritis.

Using the new non-steroidal anti-inflammatory agent meloxicam (Mel), comparative investigations on pharmacokinetics and metabolism show good agreement between results in man and in the rat. To

Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa

Whether selective inhibition of prostaglandin production, assayed as PGE2-like activity, in the inflammatory exudate can be achieved in vivo is investigated and it is reported here that it can.
...